143 related articles for article (PubMed ID: 20806940)
1. Crystal structures of HLA-A*0201 complexed with Melan-A/MART-1(26(27L)-35) peptidomimetics reveal conformational heterogeneity and highlight degeneracy of T cell recognition.
Douat-Casassus C; Borbulevych O; Tarbe M; Gervois N; Jotereau F; Baker BM; Quideau S
J Med Chem; 2010 Oct; 53(19):7061-6. PubMed ID: 20806940
[TBL] [Abstract][Full Text] [Related]
2. Structures of MART-126/27-35 Peptide/HLA-A2 complexes reveal a remarkable disconnect between antigen structural homology and T cell recognition.
Borbulevych OY; Insaidoo FK; Baxter TK; Powell DJ; Johnson LA; Restifo NP; Baker BM
J Mol Biol; 2007 Oct; 372(5):1123-36. PubMed ID: 17719062
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and Biological Evaluation of Hapten-Clicked Analogues of The Antigenic Peptide Melan-A/MART-1
Tarbe M; Miles JJ; Edwards ESJ; Miles KM; Sewell AK; Baker BM; Quideau S
ChemMedChem; 2020 May; 15(9):799-807. PubMed ID: 32162475
[TBL] [Abstract][Full Text] [Related]
4. Synthetic anticancer vaccine candidates: rational design of antigenic peptide mimetics that activate tumor-specific T-cells.
Douat-Casassus C; Marchand-Geneste N; Diez E; Gervois N; Jotereau F; Quideau S
J Med Chem; 2007 Apr; 50(7):1598-609. PubMed ID: 17328535
[TBL] [Abstract][Full Text] [Related]
5. Peptide-specific CD8+ T-cell evolution in vivo: response to peptide vaccination with Melan-A/MART-1.
Jäger E; Höhn H; Necker A; Förster R; Karbach J; Freitag K; Neukirch C; Castelli C; Salter RD; Knuth A; Maeurer MJ
Int J Cancer; 2002 Mar; 98(3):376-88. PubMed ID: 11920589
[TBL] [Abstract][Full Text] [Related]
6. Crystal structures of two closely related but antigenically distinct HLA-A2/melanocyte-melanoma tumor-antigen peptide complexes.
Sliz P; Michielin O; Cerottini JC; Luescher I; Romero P; Karplus M; Wiley DC
J Immunol; 2001 Sep; 167(6):3276-84. PubMed ID: 11544315
[TBL] [Abstract][Full Text] [Related]
7. Improved detection of melanoma antigen-specific T cells expressing low or high levels of CD8 by HLA-A2 tetramers presenting a Melan-A/Mart-1 peptide analogue.
Maeurer MJ; Necker A; Salter RD; Castelli C; Höhn H; Karbach J; Freitag K; Neukirch C; Knuth A; Jäger E
Int J Cancer; 2002 Jan; 97(1):64-71. PubMed ID: 11774245
[TBL] [Abstract][Full Text] [Related]
8. Increased immunogenicity of an anchor-modified tumor-associated antigen is due to the enhanced stability of the peptide/MHC complex: implications for vaccine design.
Borbulevych OY; Baxter TK; Yu Z; Restifo NP; Baker BM
J Immunol; 2005 Apr; 174(8):4812-20. PubMed ID: 15814707
[TBL] [Abstract][Full Text] [Related]
9. Identification of a public CDR3 motif and a biased utilization of T-cell receptor V beta and J beta chains in HLA-A2/Melan-A-specific T-cell clonotypes of melanoma patients.
Serana F; Sottini A; Caimi L; Palermo B; Natali PG; Nisticò P; Imberti L
J Transl Med; 2009 Mar; 7():21. PubMed ID: 19317896
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxic T lymphocytes define multiple peptide isoforms derived from the melanoma-associated antigen MART-1/Melan-A.
Jäger E; Höhn H; Karbach J; Momburg F; Castelli C; Knuth A; Seliger B; Maeurer MJ
Int J Cancer; 1999 Jun; 81(6):979-84. PubMed ID: 10362148
[TBL] [Abstract][Full Text] [Related]
11. Structural basis for the presentation of tumor-associated MHC class II-restricted phosphopeptides to CD4+ T cells.
Li Y; Depontieu FR; Sidney J; Salay TM; Engelhard VH; Hunt DF; Sette A; Topalian SL; Mariuzza RA
J Mol Biol; 2010 Jun; 399(4):596-603. PubMed ID: 20417641
[TBL] [Abstract][Full Text] [Related]
12. Overlapping peptides of melanocyte differentiation antigen Melan-A/MART-1 recognized by autologous cytolytic T lymphocytes in association with HLA-B45.1 and HLA-A2.1.
Schneider J; Brichard V; Boon T; Meyer zum Büschenfelde KH; Wölfel T
Int J Cancer; 1998 Jan; 75(3):451-8. PubMed ID: 9455808
[TBL] [Abstract][Full Text] [Related]
13. Amino acid substitutions at position 97 in HLA-A2 segregate cytolysis from cytokine release in MART-1/Melan-A peptide AAGIGILTV-specific cytotoxic T lymphocytes.
Maeurer MJ; Chan HW; Karbach J; Salter RD; Knuth A; Lotze MT; Storkus WJ
Eur J Immunol; 1996 Nov; 26(11):2613-23. PubMed ID: 8921947
[TBL] [Abstract][Full Text] [Related]
14. A new generation of Melan-A/MART-1 peptides that fulfill both increased immunogenicity and high resistance to biodegradation: implication for molecular anti-melanoma immunotherapy.
Blanchet JS; Valmori D; Dufau I; Ayyoub M; Nguyen C; Guillaume P; Monsarrat B; Cerottini JC; Romero P; Gairin JE
J Immunol; 2001 Nov; 167(10):5852-61. PubMed ID: 11698460
[TBL] [Abstract][Full Text] [Related]
15. Germ line-governed recognition of a cancer epitope by an immunodominant human T-cell receptor.
Cole DK; Yuan F; Rizkallah PJ; Miles JJ; Gostick E; Price DA; Gao GF; Jakobsen BK; Sewell AK
J Biol Chem; 2009 Oct; 284(40):27281-9. PubMed ID: 19605354
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of nonreplicating recombinant vaccinia expressing HLA-A201 targeted or complete MART-1/Melan-A antigen.
Schütz A; Oertli D; Marti WR; Noppen C; Padovan E; Spagnoli GC; Heberer M; Zajac P
Cancer Gene Ther; 2001 Sep; 8(9):655-61. PubMed ID: 11593334
[TBL] [Abstract][Full Text] [Related]
17. Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers.
Bioley G; Jandus C; Tuyaerts S; Rimoldi D; Kwok WW; Speiser DE; Tiercy JM; Thielemans K; Cerottini JC; Romero P
J Immunol; 2006 Nov; 177(10):6769-79. PubMed ID: 17082590
[TBL] [Abstract][Full Text] [Related]
18. Suboptimal activation of CD8(+) T cells by melanoma-derived altered peptide ligands: role of Melan-A/MART-1 optimized analogues.
Carrabba MG; Castelli C; Maeurer MJ; Squarcina P; Cova A; Pilla L; Renkvist N; Parmiani G; Rivoltini L
Cancer Res; 2003 Apr; 63(7):1560-7. PubMed ID: 12670905
[TBL] [Abstract][Full Text] [Related]
19. Functional analysis of HLA-A*0201/Melan-A peptide multimer+ CD8+ T cells isolated from an HLA-A*0201- donor: exploring tumor antigen allorestricted recognition.
Dutoit V; Guillaume P; Romero P; Cerottini JC; Valmori D
Cancer Immun; 2002 Jul; 2():7. PubMed ID: 12747752
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxic T-lymphocyte responses in melanoma through in vitro stimulation with the Melan-A peptide analogue A27L: a qualitative analysis.
Palermo B; Campanelli R; Garbelli S; Mantovani S; Robustelli Della Cuna G; Necker A; Manganoni AM; Carella G; Rivoltini L; Lantelme E; Giachino C
Melanoma Res; 2002 Oct; 12(5):491-8. PubMed ID: 12394191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]